Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 An anti-peptide antibody that recognizes a neo-antigen in the CR1 stump remaining on erythrocytes after proteolysis.

Literature DB >> 1370772

An anti-peptide antibody that recognizes a neo-antigen in the CR1 stump remaining on erythrocytes after proteolysis.

J E Barbosa¹, R A Harrison, P J Barker, P J Lachmann.

Abstract

Previous studies of erythrocyte CR1 levels in systemic lupus erythematosus (SLE) and other diseases with in vivo complement activation have led to the conclusion that CR1 levels fall because of loss of CR1 from erythrocytes by proteolysis--predominantly in the liver. In order to measure the existence of proteolysed CR1 remnants on erythrocytes an antibody was raised to a peptide corresponding to the CR1 sequence between the proximal standard consensus repeat (SCR) and the transmembrane segment. This antipeptide antibody recognizes a neo-antigen found on trypsinized erythrocytes which has been demonstrated to represent the 'CR1-stump'. The anti-'CR1-stump' antiserum detects proteolysed CR1 on the ex vivo erythrocytes of a patient with cold haemolytic antibody disease (CHAD). However, higher affinity antibodies will be needed to make anti-CR1-stump a satisfactory diagnostic reagent.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1992 PMID： 1370772 PMCID： PMC1554220 DOI： 10.1111/j.1365-2249.1992.tb06428.x

Source DB: PubMed Journal: Clin Exp Immunol ISSN： 0009-9104 Impact factor: 4.330

13 in total

Review 1. Complement deficiency and the pathogenesis of autoimmune immune complex disease.

Authors: P J Lachmann
Journal: Chem Immunol Date: 1990

Review 2. Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases.

Authors: M J Walport; P J Lachmann
Journal: Arthritis Rheum Date: 1988-02

3. The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits.

Authors: D L Brown; P J Lachmann; J V Dacie
Journal: Clin Exp Immunol Date: 1970-09 Impact factor: 4.330

Review 4. Heberden oration 1986. Complement--friend or foe?

Authors: P J Lachmann
Journal: Br J Rheumatol Date: 1987-12

5. Autoantibody to the C3b/C4b receptor and absence of this receptor from erythrocytes of a patient with systemic lupus erythematosus.

Authors: J G Wilson; R M Jack; W W Wong; P H Schur; D T Fearon
Journal: J Clin Invest Date: 1985-07 Impact factor: 14.808

6. Inherited deficiency of erythrocyte complement receptor type 1 does not cause susceptibility to systemic lupus erythematosus.

Authors: F Moldenhauer; J David; A H Fielder; P J Lachmann; M J Walport
Journal: Arthritis Rheum Date: 1987-09

7. Erythrocytes transfused into patients with SLE and haemolytic anaemia lose complement receptor type 1 from their cell surface.

Authors: M Walport; Y C Ng; P J Lachmann
Journal: Clin Exp Immunol Date: 1987-09 Impact factor: 4.330

8. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.

Authors: G D Ross; W J Yount; M J Walport; J B Winfield; C J Parker; C R Fuller; R P Taylor; B L Myones; P J Lachmann
Journal: J Immunol Date: 1985-09 Impact factor: 5.422

9. Binding of model immune complexes to erythrocyte CR1 facilitates immune complex uptake by U937 cells.

Authors: W Emlen; G Burdick; V Carl; P J Lachmann
Journal: J Immunol Date: 1989-06-15 Impact factor: 5.422

10. Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins.

Authors: L B Klickstein; W W Wong; J A Smith; J H Weis; J G Wilson; D T Fearon
Journal: J Exp Med Date: 1987-04-01 Impact factor: 14.307

3 in total